FDA advisers warn of more deaths if drug is relaunched.

Ray Moynihan*

*Corresponding author for this work

Research output: Contribution to journalArticleProfessional

5 Citations (Scopus)


Advisers to the US Food and Drug Administration are warning of more serious injuries and drug related deaths if alosetron (Lotronex)—a drug for bowel disorders manufactured by GlaxoSmithKline—returns to the market later this year.
Original languageEnglish
Pages (from-to)561-561
Number of pages1
JournalBMJ (Clinical research ed.)
Issue number7364
Publication statusPublished - 14 Sept 2002


Dive into the research topics of 'FDA advisers warn of more deaths if drug is relaunched.'. Together they form a unique fingerprint.

Cite this